Capella contact: Steve Holmes

Advent Contact: Raj Parekh

Merger of 10 privately held biotech companies with highly validated programs, including Cappella Biosciences, to operate under Centessa umbrella

Centessa Pharmaceuticals was launched in February 2021 as a novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs. The company was created by the merger of ten privately held biotech companies with highly validated programs including Advent Life Sciences’ founded Capella Biosciences. Capella Bioscience has two programs: CBS001, a neutralizing therapeutic monoclonal antibody to the inflammatory membrane form of LIGHT (known as TNFSF14), for the treatment of idiopathic pulmonary fibrosis, and CBS004, a therapeutic monoclonal antibody to blood dendritic cell antigen 2 (BDCA2), for the treatment of lupus erythematosus (systemic and cutaneous) and systemic sclerosis.

Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model